Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer

Cesare Gridelli, Rosario Pepe, Sergio Palmeri, Stefano Iacobelli, Maria Gentile, Vittorio Gebbia, Carlo Garufi, Giuseppe Airoma, Giovannella Palmieri, Anna Russo, Pasquale Incoronato, Sabino De Placido, Francesco Perrone, Luigi Basilico, Luciano Rausa, Giovanni Ferrante, Angelo Raffaele Bianco

Research output: Contribution to journalArticle

Abstract

A total of 72 patients with metastatic stage IV non-small-cell lung cancer (NSCLC) were treated with combination chemotherapy comprising the MEV regimen (mitomycin C, 8 mg/m2 given i. v. on day 1; etoposide, 100 mg/m2 given i.v. on days 1-3; and vindesine, 3 mg/m2 given i.v. on day 1; treatment repeated every 3 weeks). In 64 evaluable patients, the objective response rate was 37% (complete responses, 4.7%; partial responses, 32.3%). The median survival was 7.6 months for all patients. The treatment was very well tolerated. MEV proved to be an active and non-toxic regimen for the treatment of metastatic NSCLC.

Original languageEnglish
Pages (from-to)405-407
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume28
Issue number5
DOIs
Publication statusPublished - Sep 1991

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Gridelli, C., Pepe, R., Palmeri, S., Iacobelli, S., Gentile, M., Gebbia, V., Garufi, C., Airoma, G., Palmieri, G., Russo, A., Incoronato, P., De Placido, S., Perrone, F., Basilico, L., Rausa, L., Ferrante, G., & Bianco, A. R. (1991). Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 28(5), 405-407. https://doi.org/10.1007/BF00685698